Lakefront Biotherapeutics (LKFT)
29.73
+0.22
(+0.75%)
USD |
NASDAQ |
Oct 09, 16:00
29.74
+0.02
(+0.05%)
After-Hours: 20:00
Lakefront Biotherapeutics Total Liabilities (Quarterly) : 100.11M for June 30, 2026
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 100.11M |
| March 31, 2026 | 137.18M |
| December 31, 2025 | 200.42M |
| September 30, 2025 | 1.251B |
| June 30, 2025 | 1.379B |
| March 31, 2025 | 1.376B |
| December 31, 2024 | 1.283B |
| September 30, 2024 | 1.462B |
| June 30, 2024 | 1.479B |
| March 31, 2024 | 1.584B |
| December 31, 2023 | |
| September 30, 2023 | 1.937B |
| June 30, 2023 | 2.115B |
| March 31, 2023 | 2.246B |
| December 31, 2022 | 2.357B |
| September 30, 2022 | 2.235B |
| June 30, 2022 | 2.502B |
| March 31, 2022 | 2.730B |
| December 31, 2021 | 2.900B |
| September 30, 2021 | 3.146B |
| June 30, 2021 | 3.282B |
| March 31, 2021 | 3.424B |
| December 31, 2020 | 3.729B |
| September 30, 2020 | 3.529B |
| June 30, 2020 | 3.457B |
| Date | Value |
|---|---|
| March 31, 2020 | 3.459B |
| December 31, 2019 | 3.584B |
| September 30, 2019 | 3.616B |
| June 30, 2019 | 244.25M |
| March 31, 2019 | 252.02M |
| December 31, 2018 | 257.49M |
| September 30, 2018 | 345.35M |
| June 30, 2018 | 372.08M |
| March 31, 2018 | 406.49M |
| December 31, 2017 | 329.37M |
| September 30, 2017 | 348.09M |
| June 30, 2017 | 341.40M |
| March 31, 2017 | 347.24M |
| December 31, 2016 | 342.41M |
| September 30, 2016 | 375.65M |
| June 30, 2016 | 374.08M |
| March 31, 2016 | 399.69M |
| December 31, 2015 | 84.20M |
| September 30, 2015 | 47.17M |
| June 30, 2015 | |
| March 31, 2015 | |
| December 31, 2014 | |
| September 30, 2014 | |
| June 30, 2014 | |
| March 31, 2014 |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Liabilities (Quarterly) Benchmarks
| Gilead Sciences, Inc. | 37.62B |
| ACADIA Pharmaceuticals, Inc. | 436.29M |
| Alkermes Plc | 2.585B |
| Alnylam Pharmaceuticals, Inc. | 4.205B |
| Amarin Corp. Plc | 180.75M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 3.831B |
| Shareholders Equity (Quarterly) | 3.731B |
| Debt to Equity Ratio | 0.0019 |
| Current Ratio | 32.82 |
| Net Debt Paydown Yield | 0.05% |